Salarius amends Decoy merger: removes $2M threshold, changes conversion price adjustment

Decoy Therapeutics Inc.

Fourth Amendment dated July 29, 2025 removes $2M threshold for 'subsequent financing' triggering conversion adjustment.
Conversion price adjustment changes from weighted average to actual per share offering price in subsequent financings.
One-year limitation on conversion ratio adjustments eliminated; adjustments apply until stockholder approval and Nasdaq listing standards met.
Amendments intended to induce holders of Decoy convertible/non-convertible notes to consent and convert.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.